Modifiers JW and JZ: Billing Drug Wastage Defensibly

JW and JZ are a matched pair, and that is the whole point of them. Since 1 July 2023, a claim for a separately payable Part B drug from a single-dose container has to say one of two things: JW — this much was discarded, or JZ — nothing was discarded. Silence is no longer an option, which is why JZ exists at all.

Treating them as two unrelated modifiers is the first mistake. The second is treating the JW line as a way to recover the cost of a wasted vial. It is not a reimbursement mechanism you elect into; it is a statement about the physical fate of a labelled quantity of drug, and it has to match the medical record and — in practice — the waste stream.

The Decision Rule

Work through these in order for every separately payable Part B drug claim line.

1. Is the drug supplied in a single-dose container or single-use package under its FDA-approved labeling? The Claims Processing Manual (Publication 100-04, Chapter 17, Section 40) states that the JW and JZ policy applies in general to all Part B drugs separately payable that are described as single-dose or single-use per FDA labeling — including contrast agents and multiple source drugs. If the drug comes from a multiple-dose container, neither modifier applies. Contractor guidance is blunt about the consequence: a JW or JZ line on a multiple-dose container drug is returned as unprocessable.
2. Is the drug separately payable? The policy does not apply to drugs that are not separately payable — packaged OPPS or ASC drugs — or to drugs administered in an FQHC or RHC setting.
3. Was any amount actually discarded? If yes, and the amount is billable (see the billing-unit rule below), the claim carries two lines and the discard line takes JW. If no, the claim carries one line with JZ.

CMS maintains a list of billing and payment codes that may require the JW and JZ modifiers, published as a document on cms.gov. Where a drug’s status is unclear, the code list and the FDA labeling settle it, not local practice.

What “Discarded” Means — and What It Does Not

The manual’s definition is more precise than the everyday meaning, and the precision matters. The discarded amount is any amount that is not part of the prescribed dose and not intended to have a therapeutic effect in the patient. The manual then closes an obvious loophole: even if certain amounts are extracted from the vial, or are required to be in the vial in order to administer the prescribed dose, they are not considered used if they were not intended for therapeutic effect as part of the prescribed dose. Generally, the discarded amount is the labelled amount on the single-dose container — or containers, if more than one was needed — minus the dose actually administered.

Payment is available for the discarded amount as well as the dose, up to the amount indicated on the vial or package label. That ceiling is the outer boundary of what the policy will ever pay for waste.

The claim construction

For the administered amount: one claim line with the drug’s billing and payment code, no modifier, and the number of units administered. For the discarded amount: a second line with the same code, the JW modifier, and the number of units discarded. Both lines are processed for payment.

The manual’s worked example: a single-dose container labelled to contain 100 units, 95 administered, 5 discarded. The 95-unit dose is billed on one line and the 5 discarded units on another with JW.

For JZ, there is only one line: the code, the JZ modifier, and the units administered.

Neither policy requires the claim lines to account for only whole vials. That is stated explicitly for both modifiers, and it resolves a question that otherwise generates a lot of unnecessary rounding.

The billing-unit rule that catches people out

JW is not permitted when the actual dose administered is less than the billing unit. The manual’s example: one billing unit equals 10 mg in a single-use vial; a 7 mg dose is administered and 3 mg discarded. The 7 mg dose is billed as one billing unit — which already represents the full 10 mg — on a single line, and that line is processed for payment of the total 10 mg administered and discarded. Adding a second line with JW for the 3 mg would produce an overpayment, so it is not permitted.

Generalised: where the billing unit is equal to or greater than the total actual dose plus the amount discarded, JW is not permitted. For dates of service from 1 July 2023, JZ is used in that circumstance instead. This is the single most common source of an unnecessary JW line, and it is arithmetic rather than judgement — compare the dose plus discard against the billing unit before building a second line.

What the Record Must Show

The manual states the documentation requirement in one sentence: providers must record the discarded amounts of drugs and biologicals in the patient’s medical record. That is the whole formal requirement, and it is where most JW exposure sits, because the requirement is easy to satisfy in principle and easy to leave undone in practice.

A defensible JW record generally shows:

• The labelled vial quantity, the dose administered, and the amount discarded — the three numbers the claim lines assert, recorded contemporaneously rather than reconstructed from the claim.
• Vial size selection consistent with the dose. Repeatedly drawing a small dose from the largest available vial produces large, entirely legitimate-looking JW amounts, and it is exactly the pattern that draws scrutiny. The manual opens Section 40 by stating that CMS encourages providers to administer drugs in a way that uses them most efficiently, in a clinically appropriate manner. Where a smaller vial exists and was not used, the record should show why.
• Witness or dual-verification of waste where local policy requires it — universal for controlled substances, and common practice for hazardous drugs.
• Consistency with the physical waste record. This is the part that billing guidance never mentions and auditors do notice.

Where the Billing Record Meets the Waste Stream

A JW line is an assertion that a specific quantity of drug was discarded. For most Part B drugs that is unremarkable. For antineoplastics and other hazardous drugs it is not, because the same event generates a second official record — the one created by your hazardous-waste and USP 800 handling procedures.

Two record sets describing the same physical act should agree. In practice they are maintained by different teams under different rules, and nobody reconciles them until someone from outside asks. Considerations worth building in deliberately:

• Antineoplastic waste has its own disposal path — trace versus bulk chemotherapy waste, RCRA-listed drug determinations, and segregation requirements that are entirely separate from the claim. See CASRAI’s guide to chemotherapy waste disposal.
• USP General Chapter 800 governs the handling and compounding environment for hazardous drugs, including containment and the documentation around preparation. Where a billing supplier is discarding during preparation before supplying a drug — a scenario the manual addresses directly — the preparation record and the JW line are describing the same moment. See USP 800 cleanroom requirements.
• Pharmaceutical waste disposal rules determine what happens to the discarded volume physically, and generate their own manifests and logs — see pharmaceutical waste disposal and, for the shipping paperwork, the hazardous waste manifest.

The compliance point is not that one regime governs the other — they are independent. It is that a JW quantity that cannot be reconciled with the pharmacy’s own preparation and waste documentation is a discrepancy someone will eventually have to explain, and reconciling as a matter of routine is far cheaper than reconciling under review.

The Exceptions Worth Knowing

• Vaccines. JW and JZ are not required for vaccines described under section 1861(s)(10) of the Act furnished from single-dose containers. The manual’s reasoning is operational: influenza, pneumococcal and COVID-19 vaccines are often roster billed by mass immunisers, roster billing cannot accommodate modifiers, and requiring them would impair access.
• Suppliers who do not administer the drug. For dates of service in calendar year 2024, a billing supplier not administering the drug billed separately payable single-dose container Part B drugs with JZ. From 1 January 2025, JW is required if such a supplier discards amounts during the preparation process before supplying the drug to the patient, and JZ if nothing was discarded in preparation.
• Multiuse vials and home dialysis ESAs. Multiuse vials are generally not subject to payment for discarded amounts — with a narrow exception for self-administered erythropoiesis-stimulating agents for Method I home dialysis patients, where the renal facility bills JW for ESA appropriately discarded because of vial expiration, an interruption in the plan of care, or unused supply after a patient’s death. This does not apply to Method II home dialysis patients.
• Competitive Acquisition Program drugs. JW is not used on CAP drug claims; the manual points to a separate section for the discarded-remainder discussion there.

The Misuse That Triggers Denials and Audits

1. JW or JZ on a multiple-dose container. Returned as unprocessable — a workflow cost, not just a payment delay, because unprocessable returns generally have to be corrected and resubmitted rather than appealed.
2. A JW line where the billing unit already covers the dose plus the discard. The manual identifies this as producing an overpayment, which is the category of error that turns into a refund obligation rather than a denial.
3. Omitting JZ entirely. Since 1 July 2023 the attestation is required on separately payable single-dose container drugs with no waste. An omitted JZ is not a neutral silence.
4. JW amounts unsupported by the medical record. The recording requirement is explicit, and a JW quantity with no contemporaneous documentation is an unsupported claim for payment.
5. Systematic oversized-vial selection. Not prohibited by the modifier policy as such, but it sits directly against CMS’s stated expectation of efficient, clinically appropriate use, and it is visible in claims data at the practice level.

JW and JZ vs. Their Nearest-Confused Siblings

JW vs. JZ

The same fact pattern with opposite answers, and they are mutually exclusive on a given drug line: JW reports a discarded quantity on a second line; JZ attests that there was none. Where the billing unit already absorbs the discard, JZ is the correct modifier even though something was physically thrown away — which is the one case where the billing answer and the clinical description genuinely diverge, and the manual resolves it in favour of avoiding an overpayment.

JW/JZ vs. modifier KX

Both are attestations, which is why they get grouped mentally, but they attest to entirely different things. Modifier KX asserts that the requirements of an applicable medical policy have been met. JZ asserts a physical fact about a vial. KX is policy-relative and varies by jurisdiction; JZ means the same thing everywhere.

JW/JZ vs. modifier GA

Modifier GA concerns expected non-coverage and beneficiary liability. It has nothing to do with quantity, and a drug-waste question is never answered by shifting liability to the patient — the discarded amount is payable under the policy or it is not.

JW/JZ vs. modifier 76

Modifier 76 concerns repeated services. Multiple administrations of a drug in a day are a units and MUE question on the drug code, not a repeat-procedure question.

Where Jurisdiction Matters

The JW and JZ policy is national — it comes from the Claims Processing Manual and a CMS-published code list, not from Local Coverage Determinations — so there is less jurisdictional variation here than almost anywhere else in the modifier set. What still varies is contractor operational handling: how a MAC returns an incorrectly-modified line, what documentation it requests on a post-payment review of high JW volumes, and how it applies MUE values to drug codes.

Non-Medicare payers are a different matter entirely. Many have adopted JW-style waste billing, but the definitions, the code lists and the acceptance of a JZ attestation are payer-specific. Do not assume a commercial payer’s waste policy tracks the Medicare rule, and do not assume the reverse either.

Frequently Asked Questions

Is the JZ modifier mandatory?

For dates of service from 1 July 2023, A/B MACs and DME MACs require JZ to attest that there were no discarded amounts of a drug from a single-dose container or single-use package for which JW would otherwise have been required. It applies to claims for drugs separately payable under Part B.

Can JW be used on a multi-dose vial?

No. The policy is expressly inappropriate for drugs from multiple-dose containers, and such lines are returned as unprocessable. The narrow exception in the manual is self-administered ESAs for Method I home dialysis patients.

What if the dose is smaller than one billing unit?

Bill a single line for one billing unit and do not add a JW line — the unit already represents the full labelled quantity, so a JW line would overpay. From 1 July 2023, use JZ in that situation.

Do JW and JZ apply to vaccines?

Not to the vaccines described under section 1861(s)(10) of the Act furnished from single-dose containers — influenza, pneumococcal and COVID-19 — because roster billing cannot accommodate modifiers.

Does a JW line have to represent a whole vial?

No. The manual states that neither the JZ policy nor the JW policy requires the claim lines to account for only whole vials.

What documentation does JW require?

The discarded amount must be recorded in the patient’s medical record. In practice, a defensible record also shows the labelled vial quantity, the administered dose, and — for hazardous drugs — consistency with the pharmacy’s own preparation and waste documentation.

Related CASRAI Resources

• Chemotherapy waste disposal — the physical record of the same discard event
• USP 800 cleanroom requirements
• Pharmaceutical waste disposal
• The hazardous waste manifest
• Modifier KX: what you are attesting to
• Modifier GA: waiver of liability and the ABN
• Modifier 76: repeat procedure by the same physician
• The False Claims Act in billing

Sources: CMS Medicare Claims Processing Manual, Publication 100-04, Chapter 17, Sections 40 and 40.1 (Rev. 13108, effective 1 January 2025); CMS “JW Modifier and JZ Modifier Policy” HCPCS code list and frequently asked questions; Noridian Healthcare Solutions modifier JW and JZ guidance. Drug code lists and effective dates change — verify against the current CMS list. General reference material, not billing advice for a specific claim.